Provista Diagnostics Inc., a company developing and commercializing protein-based diagnostic, prognostic and monitoring tests for cancers affecting women, has appointed Judith K. Wolf, M.D., as Chief Medical Officer. In this role, Dr. Wolf will guide the continued clinical progress of the company’s flagship product Videssa® Breast. Dr. Wolf will also assist in overseeing Provista’s diagnostics pipeline and aid in the identification of new diagnostic approaches for development. 

“I am excited to join the Provista team and look forward to using my clinical experience to further develop blood-based diagnostic tests,” said Judith K. Wolf, M.D., Chief Medical Officer, Provista Diagnostics, Inc. “With Videssa Breast we have the ability to help physicians detect breast cancers at the earliest stage when treatment options are the most successful.”

Dr. Wolf joins Provista from Vermillion Inc. where she served as the Chief Medical Officer. She is a renowned expert in women’s health and diagnostics and is recognized for her work in the field of gynecologic cancers. She has co-authored almost 100 peer reviewed research articles and was the principle investigator or co-investigator for nearly 12 research grants related to gynecologic cancers. Dr. Wolf has also served as the principle investigator or collaborator on over 80 protocols and has presented at more than 50 conferences, numerous scientific exhibitions and seminars

Dr. Wolf has been a professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center, and a clinical professor of the Division of Clinical Education at Arizona College of Osteopathic Medicine. Dr. Wolf is Chairman of the Medical and Scientific Advisory Board of the National Ovarian Cancer Coalition and members of several gynecologic oncology organizations including; the American Association of Cancer Research, Felix Rutledge Society, Society of Gynecologic Oncology, American Society of Clinical Oncology, and the American Gynecological and Obstetrical Society. Finally, she is a Fellow of the American College of Obstetrics and Gynecology.

“Dr. Wolf brings perspective and insights that fit perfectly with Provista’s work to advance the diagnostic technologies healthcare professionals need to provide their patients with reliable, high-confidence diagnoses in women’s cancers,” said David E. Reese, Ph.D., President and Chief Executive Officer, Provista Diagnostics Inc. “The expertise she brings to our clinical development programs and our work to publish clinical research results will be invaluable to our efforts ahead.”

Additional information about Provista Diagnostics is available at ProvistaDx.com

Information about Provista Diagnostics’ clinical trials is available at ClinicalTrials.gov